Guizhou Xinbang Pharmaceutical: Announcement of the resolution of the 2023 Annual General Meeting of Shareholders
Guizhou Xinbang Pharmaceutical: Legal Opinion of Guohao Law Firm (Shanghai) on the 2023 Annual General Meeting of Shareholders of Guizhou Xinbang Pharmaceutical Co., Ltd.
Guizhou Xinbang Pharmaceutical: Announcement on the progress of litigation matters
Xinbang Pharmaceutical: Notice of Annual General Meeting of Shareholders
Xinbang Pharmaceutical: Internal Control Self-Evaluation Report
Xinbang Pharmaceutical: Announcement on the Appointment of the Company's 2024 Auditor
Xinbang Pharmaceutical: Notice on matters involving litigation
Xinbang Pharmaceutical: Announcement on changing signed project partners and project quality reviewers
Xinbang Pharmaceutical: Announcement on Election of Staff Supervisors for the 9th Board of Supervisors
Xinbang Pharmaceutical: Announcement on the Appointment of Senior Company Executives and Other Relevant Personnel
Xinbang Pharmaceutical: Legal Opinion of Guohao Attorney (Shanghai) Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Guizhou Xinbang Pharmaceutical Co., Ltd.
Xinbang Pharmaceutical: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Xinbang Pharmaceutical: Announcement on early election of the board of directors
Xinbang Pharmaceutical: Announcement on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Xinbang Pharmaceuticals: Announcement on the Early Election of the Supervisory Board
Xinbang Pharmaceutical: Announcement on the completion of the company\'s commercial and commercial changes
Xinbang Pharmaceutical: Legal Opinion of Guohao Attorney (Shanghai) Firm on the 2024 First Extraordinary General Meeting of Shareholders of Guizhou Xinbang Pharmaceutical Co., Ltd.
Xinbang Pharmaceutical: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Xinbang Pharmaceuticals: Statutory Amendments
Xinbang Pharmaceutical: Announcement on Convening the First Extraordinary General Meeting of Shareholders in 2024
No Data